Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and regional adrenalectomy for stage II-III adrenocortical carcinoma
2026-525406-36-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, doxorubicin, sodium thiosulfate and sodium nitrite in adrenal cancer (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Local or peritoneal recurrence within 36 months. Planned start Sep 2026; status: authorised.
02
Drugs
cisplatindoxorubicinsodium thiosulfatesodium nitrite
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2026-525406-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525406-36-00.